

Ref: NLL\CS\2010-

Dated: 08.09.2010

BY FAX / COURIER

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub. Investors Information Release

Dear Sirs,


Please find attached herewith an Investor Information release that the company has received approval from Korean FDA (KFDA) for key product i.e. Cefuroxime Axetil (Amorphous).

This is for your information and record please.

Thanking you,

Yours faithfully,

For NECTAR LIFESCIENCES LTD.


SUNDER LAL
Company Secretary

- CC: 1. Singapore Exchange Securities Trading Limited,
2 Shenton Way, #19-00 SGX Centre 1, Singapore 068804,
Tel.: (0065) 6236 8888, Fax: (0065) 65357919.
Ref.: Common Code for Bonds: 024957900, ISIN for the Bonds:
XS0249579003
2. Société de la Bourse de Luxembourg S.A., B.P. 165, L-2011 Luxembourg.
Telephone: (00352) 47 79 36 - 1, Fax: (00352) 47 32 98.
Ref.: Common Code for the GDRs: 039031680, ISIN for the GDRs:
US63975T1051, CUSIP of Company's GDRs: 63975T 105



NECTAR LIFESCIENCES LIMITED

Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

***NecLife announces the receipt of KFDA approval for
entry into South Korea***

Chandigarh, September 7, 2010

Nectar Lifesciences Limited (NecLife), a leading integrated pharmaceutical organization in India, today announced that it has received approval from Korean FDA (KFDA) for key product i.e. Cefuroxime Axetil (Amorphous).

Business Opportunities in Korea


The KFDA approval marks a significant achievement and demonstrates further progress made by the Company in the regulated markets. South Korea with a GDP of USD 784 billion is well poised to register steady growth in the pharma market in recent future. Currently, the market size of Pharma in South Korea is ~ USD 16.5 billion and is expected to increase to ~ USD 21.2 billion by 2011. NecLife expects business potential for the approved molecule "Cefuroxime Axetil Amorphous" to be ~ USD 10 million.

Commenting on this development, Mr. Dinesh Dua, CEO & Director of Nectar Lifesciences Limited said:

"I am delighted to share that we have received the KFDA approval to enter the South Korean market. This is an important milestone and in line with our strategy of having greater presence in regulated markets. We are optimistic about the new market as we believe South Korea is well placed to register substantial growth in coming years. This approval enables us to further augment our position in the cephalosporin market in three major molecules.

We remain excited about the current scenario of the pharma markets around the globe and are making stable progress towards securing approvals in other key markets"

Certified to be true copy
For NECTAR LIFESCIENCES LTD.


SUNDER LAL
Company Secretary

**About Nectar Lifesciences Limited (NecLife)**

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and semi-synthetic penicillin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 2 oral molecules and global No. 2 position in one sterile molecule. The Company has 11 manufacturing facilities - eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, semisynthetic, penicillin and other non-cephalosporin APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts


Dinesh Dua
Nectar Lifesciences Limited
Phone: +91 172 304 7766
Fax: +91 172 503 3537
Email: dinesh.dua@neclife.com

Ishan Selarka
Citigate Dewe Rogerson
Phone : +91 22 4007 5032
Fax: 022 2284 4561
Email: ishan@cdr-india.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.

Certified to be true copy

For NECTAR LIFESCIENCES LTD.


SUNDER LAL
Company Secretary